At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects
In Brief
A Phase 1 clinical trial evaluating Lasmiditan and Placebo for Healthy. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate the safety and tolerability of lasmiditan in healthy Japanese and Caucasian participants. The study will also investigate how much lasmiditan gets into the bloodstream and how long it takes the body to get rid of lasmiditan when given to Japanese and Caucasians. The study will last up to 47 days for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionAug 2018
TodayJul 2026
First PostedJul 9, 2018
Enrollment StartJun 27, 2018
Primary CompletionAug 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 8.0 years ago
Interventions
Lasmiditandrug
Administered orally.
Placebodrug
Administered orally.